DIABETES, ACUTE LUNG INJURY AND THE ANTI-INFLAMMATORY PROPERTIES OF ROSIGLITAZO

糖尿病、急性肺损伤和罗格列佐的抗炎特性

• 批准号: 7603680
• 负责人: Gregory B Martin
• 金额: $ 0.04万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603680
• 关键词: Acute Lung Injury; Alveolar Macrophages; Anti-Inflammatory Agents; Anti-inflammatory; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Funding; Grant; Institution; Non-Insulin-Dependent Diabetes Mellitus; Patients; Property; Purpose; Research; Research Personnel; Resources; Source; United States National Institutes of Health; rosiglitazone

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine the effects of rosiglitazone on PPAR-par activity in alveolar macrophages from patients with Type 2 diabetes.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 本研究的目的是确定罗格列酮对 2 型糖尿病患者肺泡巨噬细胞 PPAR-par 活性的影响。